| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6677358 | NOVO NORDISK INC | NIDDM regimen |
Jun, 2018
(5 years ago) | |
Prandimet is owned by Novo Nordisk Inc.
Prandimet contains Metformin Hydrochloride; Repaglinide.
Prandimet has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Prandimet are:
- US6677358
Prandimet was authorised for market use on 23 June, 2008.
Prandimet is available in tablet;oral dosage forms.
Prandimet can be used as use of repaglinide in combination with metformin to lower blood glucose.
The generics of Prandimet are possible to be released after 12 June, 2018.
Drugs and Companies using METFORMIN HYDROCHLORIDE; REPAGLINIDE ingredient
Market Authorisation Date: 23 June, 2008
Treatment: Use of repaglinide in combination with metformin to lower blood glucose
Dosage: TABLET;ORAL
How can I launch a generic of PRANDIMET before it's drug patent expiration?
More Information on Dosage
PRANDIMET family patents
